ArticleBMC endocrine disorders2025
Estimated glucose disposal rate and mortality risk in cardiovascular-kidney-metabolic syndrome: a population-based study.
Article in BMC endocrine disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundCardiovascular-kidney-metabolic (CKM) syndrome is a systemic disorder characterized by the interrelated dysfunction of metabolic abnormalities, chronic kidney disease, and cardiovascular injury, significantly increasing the risk of cardiovascular events and all-cause mortality. Insulin resistance (IR) plays an important role in the development and progression of CKM syndrome, but the relationship between estimated glucose disposal rate (eGDR) and mortality risk in CKM syndrome patients remains unclear, particularly across different glucose metabolic states.
methodsThis cohort study used data from the National Health and Nutrition Examination Survey (NHANES 1999-2018) for CKM syndrome patients. We employed Cox regression and restricted cubic spline (RCS) analysis to assess the relationship between eGDR and mortality. Stratified analyses by glucose metabolism status and ROC curves compared the predictive performance of eGDR with TyG and HOMA-IR.
resultseGDR was significantly associated with all-cause and cause-specific mortality (P < 0.05). RCS analysis revealed a nonlinear relationship between eGDR and all-cause (P for non-linear = 0.041) and diabetes-specific mortality (P for non-linear = 0.003), while a linear relationship was found with cardiovascular mortality P for non-linear = 0.278). Stratified analysis showed eGDR's strongest predictive value for all-cause mortality in diabetes, cardiovascular mortality in prediabetes, and multiple mortality outcomes in normal glucose regulation (all P < 0.05). ROC analysis demonstrated superior predictive performance of eGDR compared to TyG and HOMA-IR, especially in the CKM syndrome and normal glucose regulation groups.
conclusionLower eGDR levels were independently associated with increased risks of all-cause, cardiovascular-specific, and diabetes-specific mortality in CKM syndrome patients. The relationship between eGDR and mortality was nonlinear for some outcomes. eGDR showed superior predictive performance, especially in individuals with normal glucose regulation and prediabetes, suggesting its potential as a biomarker for risk re-stratification and early intervention in CKM syndrome. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.